ABSTRACT
Introduction Colorectal cancer (CRC) prevention programmes using faecal immunochemical testing (FIT) as the primary screen typically rely on colonoscopy for secondary and surveillance testing. Colonoscopy capacity is an important constraint, limiting the number of primary tests offered. Many European programmes lack sufficient colonoscopy capacity to provide optimal screening intensity regarding screening age ranges, intervals and FIT cut-offs. It is currently unclear how to optimise programmes within colonoscopy capacity constraints.
Design The MISCAN-Colon microsimulation model was used to determine if more effective CRC screening programmes can be identified within existing colonoscopy capacity. The model assessed 525 strategies of varying screening intervals, age ranges and FIT cut-offs, including previously unevaluated 4 and 5 year screening intervals. These strategies were compared with policy decisions taken in Ireland to provide CRC screening within available colonoscopy capacity. Outcomes estimated net costs, quality-adjusted-life-years and required colonoscopy numbers. The optimal strategies within finite colonoscopy capacity constraints were identified.
Results Combining a reduced FIT cut-off of 10 µg Hb/g, an extended screening interval of 4 years and an age range of 60-72 years requires 6% fewer colonoscopies, reduces net costs by 23% while preventing 15% more CRC deaths and saving 16% more QALYs relative to current policy.
Conclusion Previously overlooked longer screening intervals may balance optimal cancer prevention with finite colonoscopy capacity constraints. Simple changes to screening configurations could save lives, reduce costs, and relieve colonoscopy capacity pressures. These findings are directly relevant to CRC screening programmes across Europe that employ FIT-based testing and face colonoscopy capacity constraints.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
EMF reports Health and Social Care Northern Ireland and National Cancer Institute Health Economics Fellowship (grant CDV-4980-14) AGZ reports National Institutes of Health - National Cancer Institute Cancer Center support grant P30 CA008748 and from Cancer Intervention and Surveillance Modeling Network (CISNET), U01 CA199335 (EMF, AGZ, ILV, SN). JFOM is supported by the Health Research Board of Ireland under an Emerging Investigator Award EIA-2017-054. The funding agreements ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is IRB exempt.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data generated by this research has been provided, for further enquiries please contact the corresponding author.
